image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.639
-3.91 %
$ 2.4 M
Market Cap
-0.5
P/E
1. INTRINSIC VALUE

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally.[ Read More ]

The intrinsic value of one NAOV stock under the base case scenario is HIDDEN Compared to the current market price of 0.639 USD, NanoVibronix, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NAOV

image
FINANCIALS
2.28 M REVENUE
203.59%
-3.44 M OPERATING INCOME
31.44%
-3.71 M NET INCOME
31.88%
-3.6 M OPERATING CASH FLOW
48.80%
-1 K INVESTING CASH FLOW
66.67%
4.22 M FINANCING CASH FLOW
101.82%
376 K REVENUE
-53.98%
-970 K OPERATING INCOME
-43.92%
-998 K NET INCOME
-45.06%
-836 K OPERATING CASH FLOW
-51.18%
0 INVESTING CASH FLOW
100.00%
-27 K FINANCING CASH FLOW
-96.43%
Balance Sheet Decomposition NanoVibronix, Inc.
image
Current Assets 6.49 M
Cash & Short-Term Investments 3.28 M
Receivables 425 K
Other Current Assets 2.78 M
Non-Current Assets 187 K
Long-Term Investments 0
PP&E 12 K
Other Non-Current Assets 175 K
Current Liabilities 2.45 M
Accounts Payable 138 K
Short-Term Debt 10 K
Other Current Liabilities 2.31 M
Non-Current Liabilities 232 K
Long-Term Debt 0
Other Non-Current Liabilities 232 K
EFFICIENCY
Earnings Waterfall NanoVibronix, Inc.
image
Revenue 2.28 M
Cost Of Revenue 746 K
Gross Profit 1.54 M
Operating Expenses 4.97 M
Operating Income -3.44 M
Other Expenses 275 K
Net Income -3.71 M
RATIOS
67.32% GROSS MARGIN
67.32%
-150.50% OPERATING MARGIN
-150.50%
-162.55% NET MARGIN
-162.55%
-93.05% ROE
-93.05%
-55.60% ROA
-55.60%
-86.73% ROIC
-86.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NanoVibronix, Inc.
image
Net Income -3.71 M
Depreciation & Amortization 1 K
Capital Expenditures -1 K
Stock-Based Compensation 293 K
Change in Working Capital -322 K
Others 627 K
Free Cash Flow -3.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NanoVibronix, Inc.
image
NAOV has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership NanoVibronix, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jan 05, 2023
Bought 12.5 K USD
MIKA THOMAS
Director
+ 50000
0.25 USD
2 years ago
Jun 15, 2022
Bought 23.8 K USD
FASHEK CHRISTOPHER M
director:
+ 40000
0.5957 USD
4 years ago
Nov 20, 2019
Bought 50 K USD
FASHEK CHRISTOPHER M
Director
+ 25000
2 USD
2 years ago
Jun 14, 2022
Bought 2.3 K USD
BROWN STEPHEN RUSSELL
Chief Financial Officer
+ 4000
0.5739 USD
2 years ago
Jun 01, 2022
Bought 1.38 K USD
Cassirer Aurora
director:
+ 2000
0.69 USD
4 years ago
Sep 29, 2020
Bought 7.89 K USD
FASHEK CHRISTOPHER M
Director
+ 10000
0.7887 USD
7. News
NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices, today announced it has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH (“APOGEPHA”), a German pharmaceutical company, which specializes in the development, marketing, sales and distribution of urology product. businesswire.com - 1 month ago
NanoVibronix Signs Letter of Intent with Potential New Distributor ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a letter of intent with Medici Medical LTD (“Medici”), a leading distributor of medical products in the Israeli healthcare market, to explore the opportunities for distribution of the Company's UroShield device in Israel. Brian Mur. businesswire.com - 1 month ago
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The “pilot” phase of the study is the first component of the broader study. As previously announced on November 28, 2023, the company signed a Research Agree. businesswire.com - 5 months ago
NanoVibronix Issues Letter to Stockholders TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments. To Our Stockholders: We are committed to our strategic vision of developing, improving and commercializing o. businesswire.com - 6 months ago
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with CB Medical, LLC (“CB Medical”) for the sale and distribution of the Company's UroShield. UroShield is an ultrasound-based product designed to prevent bacterial colonization a. businesswire.com - 6 months ago
NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 1x1 Meetings on Thursday, May 2, 2024 ELMSFORD, NY / ACCESSWIRE / April 24, 2024 / NanoVibronix, Inc. (Nasdaq:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 9:30 AM (Pacific Time). Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. will be hosting the presentation and answering questions at the conclusion. accesswire.com - 6 months ago
NanoVibronix Issues Letter to Stockholders ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV)(“NanoVibronix”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the fourth quarter and full year 2023 and recent business developments. To Our Shareholders: We are committed to our strategic vision of developing, impr. businesswire.com - 7 months ago
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. (“Veranex”) to assist with the development of the company's next generation UroShield and PainShield products. Under the terms of the agreement, Veranex will provide certain re. businesswire.com - 7 months ago
NanoVibronix Featured in Your Bladder Health Magazine ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield is featured in Issue 103 of Your Bladder Health Magazine in an article titled ‘UroShield Prevention is better than cure.' The article highlights the effectiveness of using UroShield in the prevention of catheter associated urinary tract infec. businesswire.com - 11 months ago
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the “LOI”) with APOGEPHA Arzneimittel GmbH (“APOGEPHA”) in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix's premiere UroShield product in Germany and other European m. businesswire.com - 11 months ago
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (“RCT”) study of UroShield. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, “We are partnering with a team of distinguished resear. businesswire.com - 11 months ago
NanoVibronix Regains Nasdaq Compliance ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that on November 20, 2023, the Company received official notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the minimum stockholders' equ. businesswire.com - 11 months ago
8. Profile Summary

NanoVibronix, Inc. NAOV

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 2.4 M
Dividend Yield 0.00%
Description NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Contact 525 Executive Boulevard, Elmsford, NY, 10523 https://www.nanovibronix.com
IPO Date May 28, 2015
Employees 10
Officers Mr. Brian M. Murphy Chief Executive Officer & Director Mr. Stephen R. Brown CPA Chief Financial Officer Mr. Amir Rippel Vice President of Marketing Ms. Lindsey Harrison Vice President of Sales Dr. Harold Jacob M.D. Chief Medical Officer & Director